Ethical and Practical Considerations for the Use of Psychedelics in Psychiatry

Gregory Barber · Charles C. Dike

66 citations0/0 files storedPsychiatric Services

No readable copy stored yet — this record is metadata only.

No open-access location is known for this record yet.

Literature note Cite in a project Citation map

Psychedelics and Drug Studies Ethics in Clinical Research Neuroethics, Human Enhancement, Biomedical Innovations

Abstract

In recent years, psychedelic-assisted psychotherapies have reentered the realm of rigorous scientific inquiry, garnering much attention from both the psychiatric community and the broader public. Headlines on major media platforms frequently tout the psychedelic future of psychiatry, and patients increasingly ask about the prospect of using psychedelics during their sessions. Despite this enthusiasm, psychedelics remain in an investigational stage, and more research and regulatory work are required before psychedelics can be deemed appropriate for general clinical use. In this climate, psychiatrists are increasingly curious about the prospects of psychedelic treatments. This review's goal was to help psychiatrists better understand the complexities of the burgeoning field of psychedelic-assisted psychotherapy. The discussion encompasses issues surrounding psychedelics in their current investigational stage and issues for psychiatrists to consider should psychedelics become available for broad clinical use. This review discusses research equipoise in the context of the current enthusiasm for psychedelics, informed consent, patient vulnerability, equity and access, differences between clinical and nonclinical psychedelic uses, and psychedelic self-enhancement. As psychedelics move closer toward regulatory approval beyond research settings, it is vital that these promising treatments be used ethically. The unique features of psychedelic therapies, including the altered states of consciousness they produce and the vulnerability that such states entail for patients, require careful consideration to minimize potential ethical pitfalls. This review seeks to ensure that psychiatrists are equipped to use psychedelic psychotherapy both ethically and effectively.

Paper brief

Loading…

Cite this work

Citation unavailable for this work.

BibTeX RIS CSL-JSON

No public copy is stored for this record, so only the metadata is cited.

Citations in this library

Citation map →

Stored only when both papers are in the corpus — 66 citations exist upstream.

References

2021Trial of Psilocybin versus Escitalopram for Depression 2020Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder 2015Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study 2021MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study 2011Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness 2020Psychedelics and Psychedelic-Assisted Psychotherapy 2020A non-hallucinogenic psychedelic analogue with therapeutic potential 2018Predicting Responses to Psychedelics: A Prospective Study

Cited by

2024Psychedelic-assisted psychotherapy: where is the psychotherapy research?

Explore the map →

Papers that cite the same references — the relational fallback while embeddings are still backfilling.

Imported from OpenAlex (CC0) — nothing here is generated.